Tag Archives: U.S.

Major U.S. Health Insurers Report Big Profits, Benefiting From the Pandemic

The nation’s leading health insurers are experiencing an embarrassment of profits. Some of the largest companies, including Anthem, Humana and UnitedHealth Group, are reporting second-quarter earnings that are double what they were a year ago. And while insurance profits are capped under the Affordable Care Act, with the requirement that consumers should benefit from such… Read More »

Dr. Birx warns U.S. in new phase of coronavirus pandemic with ‘extraordinarily widespread’ cases

Deborah Birx, coronavirus response coordinator for the White House Coronavirus Task Force, speaks after a White House Coronavirus Task Force briefing at the Department of Health and Human Services on June 26, 2020 in Washington, DC. Joshua Roberts | Getty Images Dr. Deborah Birx, the White House coronavirus task force coordinator, said on Sunday that the… Read More »

Tremfya (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis

Print this page HORSHAM, PA, July 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.[1],[2] Tremfya is the first treatment… Read More »

Dr. Anthony Fauci says the average age of U.S. coronavirus patients has dropped by 15 years as Sun Belt states gets hit

The average age of new coronavirus patients has dropped by roughly 15 years compared with only a few months ago as the virus reignites in America’s Sun Belt, White House health advisor Dr. Anthony Fauci said Monday. Fauci, director of the National Institutes of Allergy and Infectious Diseases, said during a Q&A discussion with Dr. Francis… Read More »

Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita (burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO)

Print this page NOVATO, Calif. and TOKYO, June 18, 2020 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions using the… Read More »